To receive the Femtech World newsletter, sign up here.
News
Medical AI company Lunit completes US$193m acquisition
The move is expected to boost Lunit’s capabilities in AI-driven cancer diagnostics
The South Korean medical AI company Lunit has completed its acquisition of rival company Volpara Health Technologies in a deal valued at US$193m.
Lunit, which develops medical AI software for cancer screening and treatment, first announced the deal in December and was able to complete the entire transaction in eight months.
The company said the acquisition marked a “significant milestone” in its “mission to conquer cancer”.
“We are thrilled to welcome Volpara into the Lunit family. Today, we take a monumental step towards revolutionising our approach to cancer care,” said Brandon Suh, chief executive officer of Lunit.
“By combining our strengths, we are creating a formidable alliance in the industry, particularly in the US market. This merger enables us to develop and deliver innovative, life-saving solutions that meet critical needs in cancer diagnostics.
“While our initial focus remains on breast cancer, both Lunit and Volpara are committed to broadening our offerings to address a wider range of cancers and medical conditions. Together, we will enhance our technological capabilities and strengthen our mission to lead the global fight against cancer.”
Founded in 2013, Lunit uses AI-powered medical image analytics and AI biomarkers to improve cancer diagnosis and treatment. Its FDA-cleared Lunit INSIGHT suite for cancer screening serves over 3,000 hospitals and medical institutions.
Wellington-based Volpara offers software for the early detection of cancer. The strategic move, according to insiders, comes after last year Lunit conducted an “exhaustive” evaluation of possible ways to expand.
The acquisition is expected to boost Lunit’s capabilities in cancer diagnostics and create a “holistic” AI suite that will enhance breast screening.
Teri Thomas, CEO of Volpara, said: “This merger represents an exciting opportunity to enhance our impact on global healthcare.
“We can significantly improve early cancer detection and patient outcomes by integrating Volpara’s innovative breast screening technology with Lunit’s AI capabilities.”
She added: “Together, we aim to set new standards in cancer diagnostics and drive forward advancements that will benefit healthcare providers and patients globally.
“Our shared vision to conquer cancer will undoubtedly pave the way for transformative developments in medical AI.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







6 Comments